Design Therapeutics Cash Flow Statement (2020-2021) | DSGN

Cash Flow Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021
Operating Activities
Net Income -0.62M-1.46M-2.38M-3.86M
Depreciation and Depletion 0.00M0.00M0.01M0.03M0.08M
Share-based Compensation 0.00M0.01M0.01M0.42M0.65M1.24M1.24M1.56M
Gains from Investment Securities 1.72M
Non-cash Items 8.47M
Cash from Operations -2.66M-1.31M-1.86M-2.84M-3.70M-8.29M-8.16M-9.23M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles -0.00M0.01M0.06M0.00M0.15M-0.02M-0.03M-0.03M
Amortization of Deferred Charges 0.01M
Depreciation & Amortization (CF) 0.00M0.00M0.01M0.03M0.08M
Change in Working Capital
Change in Accured Expenses -1.84M0.00M2.54M0.72M1.38M-0.31M1.37M-0.03M
Investing Activities
Capital Expenditures 0.01M0.03M0.18M0.97M0.35M
Change in Acquisitions & Divestments 16.08M2.01M28.17M5.54M0.24M0.20M
Cash from Investing Activities -39.25M0.50M3.19M2.00M23.03M-21.57M-5.04M-50.06M
Financing Activities
Change in Capital Stock
Shares Issued 254.30M-0.03M
Preferred Shares Issued 44.73M124.71M
Misc.
Cash from Financing Activities 44.53M0.00M378.98M0.01M0.03M0.19M
Change in Cash 2.62M-0.81M1.33M-0.84M398.31M-29.86M-13.18M-59.09M
Beginning Cash Balance -2.62M0.81M-1.33M3.22M2.38M400.69M370.84M59.09M
Free Cash Flow -2.66M-1.31M-1.86M-2.86M-3.73M-8.47M-9.13M-9.58M
Net Cash Flow 2.62M-0.81M1.33M-0.84M398.31M-29.86M-13.18M-59.09M